Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | CLL14 trial thoughts

Constantine Tam • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Obinutuzumab Venetoclax
CLL14

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses his thoughts on the CLL14 trial (NCT02242942) of venetoclax-obinutuzumab among with untreated chronic lymphocytic leukemia (CLL) patients with a higher age or reduced fitness. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Constantine Tam

Updated efficacy and safety results of BTK degrader BGB-16673 in R/R CLL: the CaDAnCe-101study
2:22
Updated efficacy and safety results of BTK degrader BGB-16673 in R/R CLL: the CaDAnCe-101study
Constantine Tam • 5 Dec 2025
Updated data on zanubrutinib plus sonrotoclax combination as a first-line treatment for CLL
1:38
Updated data on zanubrutinib plus sonrotoclax combination as a first-line treatment for CLL
Constantine Tam • 5 Dec 2025
Long-term follow-up of SEQUOIA: zanubrutinib vs bendamustine and rituximab in treatment-naive CLL
2:47
Long-term follow-up of SEQUOIA: zanubrutinib vs bendamustine and rituximab in treatment-naive CLL
Constantine Tam • 5 Dec 2025
Long-term efficacy of zanubrutinib in patients with R/R CLL enrolled in the ALPINE trial
1:47
Long-term efficacy of zanubrutinib in patients with R/R CLL enrolled in the ALPINE trial
Constantine Tam • 5 Dec 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Constantine Tam • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Constantine Tam • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Constantine Tam • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Constantine Tam • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals